vaccine efficacy and safety

'vaccine efficacy and safety' can also refer to...

vaccine efficacy and safety

vaccine efficacy and safety

Evidence, Strategies, and Challenges for Assuring Vaccine Availability, Efficacy, and Safety

Safety and Efficacy of Inactivated Influenza Vaccines in Children

Safety, Immunogenicity, and Efficacy of Plasmodium falciparum Repeatless Circumsporozoite Protein Vaccine Encapsulated in Liposomes

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59 Years

Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy

Safety, Efficacy, and Immunogenicity of 2 Doses of Bovine-Human (UK) and Rhesus–Rhesus-Human Rotavirus Reassortant Tetravalent Vaccines in Finnish Children

Safety, Immunogenicity, and Protective Efficacy of One and Three Doses of the Tetravalent Rhesus Rotavirus Vaccine in Infants in Lima, Peru

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects

Evaluation of Live Attenuated Influenza Vaccines in Children 6–18 Months of Age: Safety, Immunogenicity, and Efficacy

Long-Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children

Trivalent Inactivated Influenza Vaccine in African Adults Infected With Human Immunodeficient Virus: Double Blind, Randomized Clinical Trial of Efficacy, Immunogenicity, and Safety

Safety, Efficacy, and Effectiveness of Live, Attenuated, Cold-Adapted Influenza Vaccine in an Indicated Population Aged 5–49 Years

Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFα biologics

A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma

Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC-Pf7, a Pox-Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria

Field Trial of a Vaccine against New World Cutaneous Leishmaniasis in an At-Risk Child Population: Safety, Immunogenicity, and Efficacy during the First 12 Months of Follow-Up


More Like This

Show all results sharing this subject:

  • Public Health and Epidemiology


Show Summary Details

Quick Reference

The safety and efficacy of vaccines are usually evaluated in phase II and phase III clinical trials. Efficacy can be measured by the postvaccination antibody titer and by the reduction, preferably to zero, in incidence of cases of the infectious disease against which the vaccine provides protection, and safety is assessed from the occurrence rate of adverse reactions among persons receiving the vaccine.

Subjects: Public Health and Epidemiology.

Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.